Key result
Low-dose urokinase increased CTPA-confirmed absorption and reduced short-term dyspnea at discharge compared to anticoagulant therapy, without affecting mortality or bleeding risk.
Why the study?
Patients with intermediate-high-risk pulmonary embolism have high risk of adverse outcomes, but the role of thrombolytic therapy in this setting remains controversial.
Does low-dose urokinase improve thrombus absorption, dyspnea, and mortality in patients with acute intermediate-high-risk pulmonary embolism compared to anticoagulation alone?
Cohort (n=81)
Yes
Does low-dose urokinase improve thrombus absorption, dyspnea, and mortality in patients with acute intermediate-high-risk pulmonary embolism compared to anticoagulation alone?
Low-dose urokinase may safely accelerate thrombus resolution and relieve dyspnea in intermediate-high-risk pulmonary embolism without increasing bleeding risk.
Answers are grounded in this paper and cite their sources.
Low-dose UK may improve absorption and dyspnea in intermediate-high-risk PE without raising bleeding or mortality; leaves open confirmation via randomized trials.
INTRODUCTION: Patients at intermediate-high risk of developing a pulmonary embolism (PE) are very likely to experience adverse outcomes, such as cardiovascular instability and death. The role of thrombolytic therapy in intermediate-high-risk PE remains controversial. OBJECTIVES: This study aimed to determine the efficacy and safety of low-dose urokinase (UK) thrombolytic therapy for intermediate-high-risk PE. PATIENTS AND METHODS: This retrospective study included 81 consecutive patients with intermediate-high-risk PE from two centers. Patients received low-dose UK or low-molecular-weight heparin (anticoagulant therapy group). The efficacy outcomes were mortality, computed tomography pulmonary angiography (CTPA)-confirmed absorption, and dyspnea. Safety was assessed as the incidence of bleedings. RESULTS: The in-hospital mortality, 9-month mortality, and long-term mortality at the last follow-up were comparable for the low-dose UK group and the anticoagulant therapy group (6.45% vs. 0%, p = 0.144, 9.68% vs. 8.16%, p = 0.815, and 12.90% vs. 12.24%, p = 0.931, respectively). CTPA-confirmed absorption at one month after admission was higher in the low-dose UK group than in the anticoagulant therapy group (p = 0.016). The incidences of short-term dyspnea at discharge and long-term dyspnea at the last follow-up were lower in the low-dose UK group than in the anticoagulant therapy group (27.59% vs. 52%, p = 0.035, 33.33% vs. 58.14%, p = 0.043, respectively). No major bleeding occurred. The incidence of minor bleeding was not significantly different between the two groups (3.23% vs. 6%, p = 0.974). CONCLUSION: In intermediate-high-risk PE, a low-dose UK might increase CTPA-confirmed absorption and improve short-term and long-term dyspnea without affecting mortality or increasing the bleeding risk.
No takes yet. Share an insight, caveat, or question.
Weng et al. (2021) conducted a cohort in Acute intermediate-high-risk pulmonary embolism (n=81). Low-dose urokinase (UK) combined with low-molecular-weight heparin (LMWH) vs. Low-molecular-weight heparin (LMWH) alone was evaluated on In-hospital mortality (p=0.144). Low-dose urokinase increased CTPA-confirmed absorption and reduced short-term dyspnea at discharge compared to anticoagulant therapy, without affecting mortality or bleeding risk.
Synapse has enriched 10 related papers. Consider them for comparative context: